Figure 5.

Characterization of Efferocytosis Activity of IPSDMs and PBDMs

(A) Efferocytosis assay of M0-IPSDMs and M0-PBDMs. Live cells (used as a negative control) and apoptotic cells were labeled with CFSE, and macrophages were stained by anti-CD11b antibody. Histogram plots of CFSE (lower panel) within the CD11b+ population (upper panel) are shown.

(B) Efferocytic index of M0-IPSDMs and M0-PBDMs. The percentage of CFSE+ macrophages was multiplied by the MFI of CFSE in order to calculate the efferocytic index. Error bars are ±SD of four independent experiments. Uncorrected Fisher's least significant differences test: ^∗p < 0.05, ^∗∗p < 0.01.

(C) Quantification of gene expression of efferocytosis-related genes CX3CR1, S1PR1, CD36, and MERTK by qPCR in M0-IPSDMs and M0-PBDMs. Unpaired t test: ^∗p < 0.05.

(D) Efferocytosis assay of different subtypes of IPSDMs and PBDMs. Live cells (used as a negative control) and apoptotic cells were labeled with CFSE, and macrophages were stained by anti-CD11b antibody. Histogram plots of CFSE (lower panel) within the CD11b+ population (upper panel) are shown.

(E) Efferocytic index of different subtypes of IPSDMs and PBDMs. The percentage of CFSE+ macrophages was multiplied by MFI of CFSE in order to calculate the efferocytic index. Data are presented as means of three biological replicates (three hiPSC lines or PBMC samples).

IPSDMs were differentiated from LU83 in (A)–(D). See also Figure S4.